Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Liminal BioSciences Inc. LMNL

Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market.


NDAQ:LMNL - Post by User

Bullboard Posts
Comment by HighteawithIntrepidon Sep 05, 2017 1:12pm
146 Views
Post# 26657205

RE:RE:Next Financing at?

RE:RE:Next Financing at?sah1: The 2 balls up in the air are the FDA yes and a potential for a deal.
PL has been overly optimistic in the past and the market, not the believers 
has adopted the position of show me the money. Therefore a lot of people that 
might add a few shares aren't buying and the fact you no longer need to sell short on
the uptick allows computerized traders to control the share price primarily because we 
don't have enough cash in the till to get to the goal line plus a margin of error.
Not the best of days for the market as a whole which isn't helping the cause.
Until PL delivers on one of the balls nothing we can do to defend the share price 
as retail investors. The health care stocks as a group have not done well. Teva 
has 20 billion in sales and a market cap of 16 billion per the BNN talking head so
as a comparable to our ratios. Call the man on us and see what he says.


Bullboard Posts